-
Product Insights
Erythrodermic Psoriasis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Erythrodermic Psoriasis - Global Clinical Trials Review, 2025" provides an overview of Erythrodermic Psoriasis Clinical trials scenario. This report provides top line data relating to the clinical trials on Erythrodermic Psoriasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Squamous Non-Small Cell Lung Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Squamous Non-Small Cell Lung Cancer - Global Clinical Trials Review, 2025" provides an overview of Squamous Non-Small Cell Lung Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Squamous Non-Small Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Alpha-1 Antitrypsin Deficiency Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Alpha-1 Antitrypsin Deficiency (A1AD) - Global Clinical Trials Review, 2025" provides an overview of Alpha-1 Antitrypsin Deficiency (A1AD) Clinical trials scenario. This report provides top line data relating to the clinical trials on Alpha-1 Antitrypsin Deficiency (A1AD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Tuberculosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Tuberculosis - Global Clinical Trials Review, 2025" provides an overview of Tuberculosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Tuberculosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Actinic (Solar) Keratosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Actinic (Solar) Keratosis - Global Clinical Trials Review, 2025" provides an overview of Actinic (Solar) Keratosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Actinic (Solar) Keratosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Pulmonary Fibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Pulmonary Fibrosis - Global Clinical Trials Review, 2025" provides an overview of Pulmonary Fibrosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Pulmonary Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Meningitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Meningitis - Global Clinical Trials Review, 2025" provides an overview of Meningitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Meningitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Dilated Cardiomyopathy (DCM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Dilated Cardiomyopathy Therapeutics. - In 2024, more than three million diagnosed prevalent cases of DCM are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast. - The treatment of DCM is primarily focused on symptom management using beta-blockers, ACE inhibitors, ARBs, MRAs, and SGLT2 inhibitors. - Currently, 34 molecules are being developed for DCM across various stages of the pipeline. - Over the past 10...
-
Sector Analysis
Hypothyroidism (HT) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hypothyroidism Therapeutics. - In 2024, more than 300 million diagnosed prevalent cases of hypothyroidism are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast. - The hypothyroidism market space is saturated with generic drugs, and thyroid-stimulating hormone agonists dominate the market. - The hypothyroidism pipeline holds seven molecules, with only one asset in Phase III development. - Over the past 10 years, the US has...
-
Sector Analysis
Hypertrophic Cardiomyopathy (HCM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hypertrophic Cardiomyopathy Therapeutics. - In 2024, more than two million diagnosed prevalent cases of HCM are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast. - HCM management has traditionally relied on generic beta-blockers and calcium channel blockers to alleviate symptoms. - A total of 34 molecules are in development for HCM, including two drugs in the pre-registration stage, two drugs in Phase III, and...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.